Saltar al contenido
Merck

Sleep fragmentation induces heart failure in a hypertrophic cardiomyopathy mouse model by altering redox metabolism.

iScience (2024-02-16)
Karthikeyan Bose, Radhika Agrawal, Thiagarajan Sairam, Jessenya Mil, Matthew P Butler, Perundurai S Dhandapany
RESUMEN

Sleep fragmentation (SF) disrupts normal biological rhythms and has major impacts on cardiovascular health; however, it has never been shown to be a risk factor involved in the transition from cardiac hypertrophy to heart failure (HF). We now demonstrate devastating effects of SF on hypertrophic cardiomyopathy (HCM). We generated a transgenic mouse model harboring a patient-specific myosin binding protein C3 (MYBPC3) variant displaying HCM, and measured the progression of pathophysiology in the presence and absence of SF. SF induces mitochondrial damage, sarcomere disarray, and apoptosis in HCM mice; these changes result in a transition of hypertrophy to an HF phenotype by chiefly targeting redox metabolic pathways. Our findings for the first time show that SF is a risk factor for HF transition and have important implications in clinical settings where HCM patients with sleep disorders have worse prognosis, and strategic intervention with regularized sleep patterns might help such patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Phosphatase Inhibitor Cocktail 2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
Cóctel de inhibidores de fosfatasa 3, DMSO solution
Sigma-Aldrich
ANTI-MYBPC3 (N-TERM) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution